Fluorescent-labeled bevacizumab (Mivenion)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameFluorescent-labeled bevacizumab (Mivenion)

Drug Alias Namefluorescent-labeled B20-4.1.1

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionVascular endothelial growth factor receptor antagonists

TargetsVascular endothelial growth factor receptor

Therapy Area/IndicationsEye Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator Companiesmivenion Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive Companiesmivenion Gmbh

Active IndicationsN/A

Inactive IndicationsEye Diseases

Other Information

ATC CodeN/A